Caplyta® (lumateperone) schizophrenia safety and tolerability profile published in the journal, international clinical psychopharmacology

Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg
ITCI Ratings Summary
ITCI Quant Ranking